In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...
Here are two options investors should consider: Johnson & Johnson ( JNJ 0.09%) and Merck ( MRK 1.54%). These two healthcare ...
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...
US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...
Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per ...
MedPage Today on MSN
Preservatives and Cancer; Pre-Op Therapy Gains Momentum; Speedier Myeloma Approvals
News, features, and commentary about cancer-related issues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results